Pat Arensdorf

Pat Arensdorf has held a variety of positions in the medical and biotechnology industries since 2005. In that year, they became the Principal of Halteres Associates, LLC, and the Executive Vice President of Tethys Bioscience, Inc. Pat then went on to become the Executive Vice President of Intersect ENT in 2005, and the Chief Executive Officer of Critical Diagnostics in 2009. In 2012, they became the General Manager of the Heart Failure Business Unit and a Strategic Consultant at Diadexus, and in 2013 they became an Advisor at ImmuMetrix. In 2016, they were the CFO and a Consultant at the Chan Zuckerberg Biohub, and the Chief Executive Officer of Bluestar Genomics, Inc. In 2021, they became the Co-Founder and Chief Executive Officer of Exai Bio.

Pat Arensdorf obtained a High School Diploma from Punahou School between 1983 and 1985. Pat then attended Princeton University from 1986 to 1990, where they earned a Bachelor's degree in Molecular Biology. In 2002, they completed an Advanced Project Management Program at Stanford University Continuing Studies. Finally, in 2003, they earned a Master's degree in Management from Stanford University Graduate School of Business as a Sloan Fellow.